A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients (OZM-065)
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
Sponsor: Merck Sharp & Dohme LLC
This PHASE2 trial investigates Stage IV Renal Cell Cancer AJCC V7 and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2019 — Nov 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Ozmosis Research Inc.
- Sunnybrook Health Sciences Centre
For direct contact, visit the study record on ClinicalTrials.gov .